presentation.mkdn 11 KB

123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336
  1. % Bioinformatic analysis of complex, high-throughput genomic and epigenomic data in the context of $\mathsf{CD4}^{+}$ T-cell differentiation and diagnosis and treatment of transplant rejection
  2. % Ryan C. Thompson \
  3. Su Lab \
  4. The Scripps Research Institute
  5. % October 24, 2019
  6. ## Organ transplants are a life-saving treatment for many
  7. \Large
  8. * 36,528 transplants performed in the USA in 2018[^1]
  9. . . .
  10. * 100 transplants every day!
  11. . . .
  12. * Over 113,000 people on the national transplant waiting list as of
  13. July 2019
  14. [^1]: Source: https://www.organdonor.gov/statistics-stories/statistics.html
  15. ## Organ transplants are a life-saving treatment for many
  16. ![Organ donation statistics for the USA in 2018[^2]](graphics/presentation/transplants-organ-CROP-RASTER.png){ height=70% }
  17. [^2]: Source: https://www.organdonor.gov/statistics-stories/statistics.html
  18. ## Rejection is an adaptive immune response against a graft
  19. * The host's adaptive immune system identifies and attacks cells
  20. bearing non-self antigens
  21. . . .
  22. * An allograft contains differnet genetic variants from the host,
  23. resulting in protein-coding differences
  24. . . .
  25. * Left unchecked, the host immune system eventually notices these
  26. alloantigens and begins attacking (rejecting) the graft
  27. . . .
  28. * Rejection is the major long-term threat to organ allografts
  29. ## Allograft rejection remains a major long-term problem
  30. ![Kidney allograft survival rates in children by transplant year[^3]](graphics/presentation/kidney-graft-survival.png){ height=65% }
  31. [^3]: Kim & Marks. "Long-term outcomes of children after solid organ transplantation". In: Clinics (2014)
  32. ## Rejection is treated with immune suppressive drugs
  33. * To prevent rejection, a graft recipient must take immune suppressive
  34. drugs for the rest of their life
  35. * The graft is periodically checked for signs of rejection, and immune
  36. suppression dosage is adjusted accordingly
  37. * Immune suppression is a delicate balance: too much leads to immune
  38. compromise; too little leads to rejection.
  39. . . .
  40. * Both diagnosis and treatment present significant challenges
  41. * Immune memory is the major contributor to long-term rejection
  42. ## My thesis topics
  43. ### Chapter 2
  44. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  45. and memory $\mathsf{CD4}^{+}$ T-cell activation
  46. ### Chapter 3
  47. Improving array-based diagnostics for transplant rejection by
  48. optimizing data preprocessing
  49. ### Chapter 4
  50. Globin-blocking for more effective blood RNA-seq analysis in primate
  51. animal model for experimental graft rejection treatment
  52. ## Today's focus
  53. ### Chapter 2
  54. \Large
  55. Genome-wide epigenetic analysis of H3K4 and H3K27 methylation in naïve
  56. and memory $\mathsf{CD4}^{+}$ T-cell activation
  57. ## Memory cells: faster, stronger, and more independent
  58. ![Memory T-cells proliferate and respond more quickly](graphics/presentation/T-cells-SVG.png)
  59. ## Memory cells are a problem for immune suppression
  60. \large
  61. Compared to naïve cells, memory cells:
  62. \normalsize
  63. * respond to a lower antigen concentration
  64. * respond more strongly at any given antigen concentration
  65. * require less co-stimulation
  66. * are somewhat independent of some types of co-stimulation required by
  67. naïve cells
  68. * evolve over time to respond even more strongly to their antigen
  69. . . .
  70. \large
  71. Result:
  72. \normalsize
  73. * Memory cells require progressively higher doses of immune suppresive
  74. drugs
  75. * Dosage cannot be increased indefinitely without compromising the
  76. immune system's ability to fight infection
  77. ## We need a better understanding of immune memory
  78. * Cell surface markers of naïve and memory $\mathsf{CD4}^{+}$ T-cells
  79. are fairly well-characterized
  80. * But internal mechanisms that allow memory cells to respond
  81. differently to the same stimulus (antigen presentation) are not
  82. well-understood
  83. . . .
  84. * A reasonable hypothesis is that some of these mechanisms are
  85. epigenetic: using histone marks or DNA methylation to regulate the
  86. expression of certain genes
  87. * We can test this hypothesis by measuring gene expression (using
  88. RNA-seq) and histone methylation (using ChIP-seq) in naïve and
  89. memory T-cells before and after activation
  90. ## Experimental design
  91. * Separately isolate naïve and memory $\mathsf{CD4}^{+}$ T-cells from
  92. 4 donors
  93. * Activate with CD3/CD28 beads
  94. * Take samples at 4 time points: Day 0 (pre-activation), Day 1 (early
  95. activation), Day 5 (peak activation), and Day 14 (post-activation)
  96. * Do RNA-seq + ChIP-seq for 3 histone marks (H3K4me2, H3K4me3, &
  97. H3K27me3) for each sample.
  98. Data generated by Sarah Lamere, published in GEO as
  99. [GSE73214](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73214)
  100. ## A few intermediate analysis steps are required
  101. ![Flowchart of workflow for data analysis](graphics/CD4-csaw/rulegraphs/rulegraph-all-RASTER300.png)
  102. ## Histone modifications are observed on consecutive histones
  103. ![Strand cross-correlation plots](graphics/CD4-csaw/csaw/CCF-plots-PAGE2-CROP-RASTER.png)
  104. ## Histone modifications are observed on consecutive histones
  105. ![ChIP-seq coverage in IL2 gene[^5]](graphics/presentation/LaMere-thesis-fig3.9-SVG-CROP.png){ height=70% }
  106. [^5]: Sarah LaMere. "Dynamic epigenetic regulation of CD4 T cell activation and memory formation". PhD thesis. TSRI, 2015.
  107. ## Finding enriched regions across the genome
  108. * Scan across the genome looking for regions with read coverage above
  109. background level in each donor using SICER peak caller
  110. * Use Irreducible Discovery Rate framework to identify peaks that are
  111. called consistently across multiple donors
  112. ![Peak-calling summary statistics](graphics/presentation/RCT-thesis-table2.2-SVG-CROP.png)
  113. ## Each histone mark has an "effective promoter radius"
  114. ![Enrichment of peaks near promoters](graphics/CD4-csaw/Promoter-Peak-Distance-Profile-PAGE1-CROP-RASTER.png)
  115. ## Peaks in promoters are correlated with gene expression
  116. <!-- TODO: Pull out one column and rotate it -->
  117. ![Expression distributions of genes with and without promoter peaks](graphics/CD4-csaw/FPKM-by-Peak-Violin-Plots-CROP-RASTER.png)
  118. ## The story so far
  119. * H3K4me2, H3K4me3, and H3K27me3 occur on many consecutive histones in
  120. broad regions across the genome
  121. * These enriched regions occur more commonly within a certain radius
  122. of gene promoters
  123. * This "effective promoter radius" is consistent across all samples
  124. for a given histone mark, but differs between histone marks
  125. * Presence or absence of a peak within this radius is correlated with
  126. gene expression
  127. . . .
  128. Next: Does the position of a histone modification within a gene
  129. promoter matter to that gene's expression, or is it merely the
  130. presence or absence anywhere within the promoter?
  131. ## H3K4me2 promoter neighborhood K-means clusters
  132. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-clusters-CROP.png)
  133. ## H3K4me2 promoter neighborhood cluster PCA
  134. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-PCA-CROP.png)
  135. ## H3K4me2 promoter neighborhood cluster expression
  136. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-neighborhood-expression-CROP.png)
  137. ## H3K4me3 promoter neighborhood K-means clusters
  138. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-clusters-CROP.png)
  139. ## H3K4me3 promoter neighborhood cluster PCA
  140. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-PCA-CROP.png)
  141. ## H3K4me3 promoter neighborhood cluster expression
  142. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-neighborhood-expression-CROP.png)
  143. ## H3K27me3 promoter neighborhood K-means clusters
  144. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-clusters-CROP.png)
  145. ## H3K27me3 promoter neighborhood cluster PCA
  146. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-PCA-CROP.png)
  147. ## H3K27me3 promoter neighborhood cluster expression
  148. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-neighborhood-expression-CROP.png)
  149. ## What have we learned?
  150. ### H3K4me2 & H3K4me3
  151. * Peak closer to promoter $\Rightarrow$ more likely gene is highly
  152. expressed
  153. * Slightly asymmetric in favor of peaks downstream of TSS
  154. . . .
  155. ### H3K27me3
  156. * Depletion of H3K27me3 at TSS associated with elevated gene
  157. expression
  158. * Enrichment of H3K27me3 upstream of TSS even more strongly associated
  159. with elevated expression
  160. * Other coverage profiles not associated with elevated expression
  161. ## Differential modification disappears by Day 14
  162. ![Differential modification between naïve and memory samples at each time point](graphics/presentation/RCT-thesis-table2.4-SVG-CROP.png)
  163. ## Convergence at Day 14 H3K4me2
  164. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me2-promoter-PCA-group-CROP.png)
  165. ## Convergence at Day 14 H3K4me3
  166. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K4me3-promoter-PCA-group-CROP.png)
  167. ## Convergence at Day 14 H3K27me3
  168. ![(Insert figure legend)](graphics/CD4-csaw/ChIP-seq/H3K27me3-promoter-PCA-group-CROP.png)
  169. ## Convergence at Day 14 RNA-seq (PC 2 & 3)
  170. ![(Insert figure legend)](graphics/CD4-csaw/RNA-seq/PCA-final-23-CROP.png)
  171. ## MOFA identifies shared variation across all 4 data sets
  172. ![(Insert figure legend)](graphics/CD4-csaw/MOFA-varExplaiend-matrix-CROP.png)
  173. ## MOFA shared variation captures convergence pattern
  174. ![(Insert figure legend)](graphics/CD4-csaw/MOFA-LF-scatter-small.png)
  175. ## What have we learned?
  176. * Almost no differential modification observed between naïve and
  177. memory at Day 14, despite plenty of differential modification at
  178. earlier time points.
  179. * RNA-seq data and all 3 histone marks' ChIP-seq data all show
  180. "convergence" between naïve and memory by Day 14 in the first 2 or 3
  181. principal coordinates.
  182. * MOFA captures this convergence pattern in one of the latent factors,
  183. indicating that this is a shared pattern across all 4 data sets.
  184. <!-- ## Slide -->
  185. <!-- ![(Insert figure legend)](graphics/CD4-csaw/LaMere2016_fig8-RASTER.png) -->
  186. ## Takeaway 1: Each histone mark has an "effective promoter radius"
  187. * H3K4me2, H3K4me3, and H3K27me3 ChIP-seq reads are enriched in broad
  188. regions across the genome, representing areas where the histone
  189. modification is present
  190. * These enriched regions occur more commonly within a certain radius
  191. of gene promoters
  192. * This "effective promoter radius" is specific to each histone mark
  193. * Presence or absence of a peak within this radius is correlated with
  194. gene expression
  195. ## Takeaway 2: Peak position within the promoter is important
  196. * H3K4me2 and H3K4me3 peaks are more strongly associated with elevated
  197. gene expression the closer they are to the TSS, with a slight bias
  198. toward downstream peaks.
  199. * H3K27me3 depletion at the TSS and enrichement upstream are both
  200. associated with elevated expression, while other patterns are not.
  201. * In all histone marks, position of modification within promoter
  202. appears to be an important factor in association with gene
  203. expression
  204. ## Takeaway 3: Expression & epigenetic state both converge at Day 14
  205. * At Day 14, almost no differential modification observed between
  206. naïve and memory cells
  207. * Naïve and memory converge visually in PCoA plots
  208. * Convergence is a shared pattern of variation across all 3 histone
  209. marks and gene expression
  210. * This is consistent with the hypothesis that the naïve cells have
  211. differentiated into a more memory-like phenotype by day 14.